Searchable abstracts of presentations at key conferences in endocrinology

ea0019s71 | Young Endocrinologist prize lecture | SFEBES2009

In search of the genetic basis of polycystic ovary syndrome and its metabolic consequences

Barber T , Wass J , Franks S , McCarthy M

Polycystic ovary syndrome (PCOS) is characterised by reproductive, hyperandrogenic and dysmetabolic features (including insulin resistance). There remain major questions about the basis of the metabolic dysfunction in PCOS and about its genetic aetiology. Having genotyped samples from >460 PCOS cases and >1300 female controls, I recently successfully identified the first genome-sequence variant (the FTO gene) to be implicated in susceptibility to PCOS (Barber <i...

ea0019p190 | Endocrine tumours and neoplasia | SFEBES2009

Expression of guanylyl cyclase-B (GC-B) receptors in a range of human pituitary adenomas: evidence for a local natriuretic peptide system

Thompson I , Ansorge O , Karavitaki N , Wass J , Fowkes R

Several recent studies have identified Npr2 gene mutations (encoding the guanylyl cyclase B (GC-B) receptor) as causing dwarfism and achondroplasia. Npr2 null mice have a similar bone phenotype, pituitary growth hormone deficiency and female infertility. As the endogenous ligand for GC-B, C-type natriuretic peptide (CNP) is expressed at high levels in the anterior pituitary of rats and mice, we examined whether components of the natriuretic peptide system were al...

ea0009p78 | Growth and development | BES2005

Testogel - An effective and acceptable androgen replacement

Meston N , Cowsill C , Wass J , Turner H

BackgroundTransdermally absorbed alcohol-based testosterone gel has presented an alternative method of gonadal therapy. This study was designed to investigate the clinical effectiveness of this alternative hormonal replacement.Method97 men requiring testosterone replacement therapy for primary (21%) or secondary (79%) hypogonadism were recruited. The subjects underwent physical examination, psychological asse...

ea0009p81 | Growth and development | BES2005

Testogel - Improves well being and libido in hypogonadal men

Cowsill C , Meston N , O'Connor M , Wass J , Turner H

BackgroundThis study was designed to monitor the clinical effectiveness of transdermal replacement. Psychological well-being was assessed by questionnaire at 3, 6 and 12MethodWe recruited 97 men requiring testosterone replacement therapy for primary (21%) or secondary (79%) hypogonadism. All had a physical examination, biochemical and haematological blood sampling (Meston et al 2004) and psychological assessm...

ea0009p98 | Endocrine tumours and neoplasia | BES2005

What is the final outcome in patients with macroprolactinoma resistant to dopamine agonists?

Trifanescu R , Karavitaki N , Coculescu M , Turner H , Wass J

BACKGROUND: Dopamine agonists are the treatment of choice in macroprolactinomas. A number of these tumours do not respond to the commonly used doses. In such cases the outcome after alternative approaches has not been clarified.AIM: To assess the response of macroprolactinomas to bromocriptine (BRC) or cabergoline (CAB) and the result of further interventions in resistant cases.PATIENTS AND METHODS: All records of the patients pres...

ea0009p110 | Endocrine tumours and neoplasia | BES2005

Symptomatic Rathke cleft cysts: systematic review of 10 cases with long follow-up

Karavitaki N , Georgas G , Ansorge O , Adams C , Wass J

Background: Rathke cleft cysts (RCC) are benign, epithelial-lined cystic lesions arising from remnants of Rathke's pouch. Although reported in 13-22% of normal autopsies, they are rarely symptomatic. Their outcome after surgery remains unclear.Aim: To analyse the clinical/laboratory features and treatment outcome of patients who presented to the Departments of Endocrinology and Neurosurgery with symptomatic RCC (histologically confirmed) between 1977-200...

ea0009p122 | Endocrine tumours and neoplasia | BES2005

Lymphocytic hypophysitis: What is the long-term outcome?

Tsametis C , Karavitaki N , Ansorge O , Turner H , Wass J

BACKGROUND: Lymphocytic hypophysitis (LHy) is an uncommon inflammatory disorder of the pituitary with features mimicking those of sellar tumours, thereby often being misdiagnosed. However, no long-term follow-up studies have been published.OBJECT: To evaluate the clinical/radiological characteristics and the prognosis of patients with LHy.PATIENTS-METHODS: The records of the patients who presented to the Department of Endocrinology...

ea0007p113 | Endocrine tumours and neoplasia | BES2004

Long acting somatostatin analogues administered by practice nurses: an audit

Fazal-Sanderson V , Thornton-Jones V , Wass J , Turner H

Background:Long acting somatostatin analogues are an effective treatment for acromegaly but require administration by nurses.To improve patient convenience we have taken care into the community with endocrine specialist nurse education of practice nurses in administration of injections.Methods:After an initial pilot study, a questionnaire was administered to patients receiving, and practice nurses administering, Somatuline Autogel(SA) n=10 and Sandostati...

ea0007p115 | Endocrine tumours and neoplasia | BES2004

The effects of pituitary tumours on cognitive function

Treece K , Wass J , Lincoln N , Page R

Surgery and radiotherapy are used in the treatment of pituitary tumours. Treatment regimens for pituitary tumours vary depending upon perceived risks of radiotherapy.The aim of the study was to determine whether pituitary disease itself, surgery or radiotherapy, affect cognitive function. This was a controlled prospective design. Two groups were studied, transphenoidal adenomectomy (TSA) pituitary patients (active), and functional endoscopic sinus surger...

ea0007p159 | Neuroendocrinology and behaviour | BES2004

Imaging of the pituitary is indicated in marginal hyperprolactinaemia (<1000 milliunits per litre) to detect microadenoma

Shore H , Karavitaki N , Turner H , Wass J

Background: In clinical practice there is considerable confusion as to whether pituitary imaging is indicated in patients presenting with a marginally elevated serum prolactin level (<1000 milliunits per litre) and no other discernible cause of hyperprolactinaemia.Objective: The aim of this study was to investigate the frequency of radiological abnormalities of the pituitary in patients presenting with marginal hyperprolactinaemia (<1000 milliunits...